CIK 0001374690
- Non-accelerated filer
- Smaller reporting company
Larimar Therapeutics, Inc.
Sign in to watch- Ticker
- LRMR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 203857670
- Phone
- +1 844-511-9056
- Business address
- THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA, 19004
- Former names
- ZAFGEN, INC., ZAFGEN INC
- Open-market buys, last 90 days
- $392,144
- in 8 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$392,144. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 30 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-01-24 | Daniel Thomas O Director | Grant or award · Stock Option (Right to Buy) | +13,280 | 13,280 | ||
| 2019-01-24 | McDonough Cameron Geoffrey Director | Grant or award · Stock Option (Right to Buy) | +11,804 | 11,804 | ||
| 2019-01-22 | McVeigh Brian Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +125,000 | 125,000 | ||
| 2019-01-22 | Hatfield Jeffrey S. Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +525,000 | 525,000 | ||
| 2019-01-22 | KIM DENNIS D Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +95,000 | 95,000 | ||
| 2019-01-22 | Allen Patricia L Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +125,000 | 125,000 | ||
| 2018-06-29 | Atlas Venture Fund VII L P 10% owner | Other disposition | −1,126,546 | 3,506,184 | ||
| 2018-06-29 | Atlas Venture Fund VII L P 10% owner | Other disposition | −234,321 | 11 | ||
| 2018-06-28 | Hughes Thomas E. See Remarks | Sale | −32,000 | $10.00 | $320K | 125,247 |
| 2018-06-06 | THOMAS FRANK E Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2018-06-06 | EVERETT WENDY Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2018-06-06 | EVERETT WENDY Director | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2018-06-06 | Barrett Peter Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2018-06-06 | LAMATTINA JOHN L Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2018-06-06 | Daniel Thomas O Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2018-06-06 | PEREZ ROBERT J Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2018-06-06 | McDonough Cameron Geoffrey Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2018-05-29 | McVeigh Brian Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +225,000 | 225,000 | ||
| 2018-03-07 | Hughes Thomas E. See Remarks | Sale | −5,000 | $10.00 | $50K | 157,247 |
| 2018-02-22 | KIM DENNIS D Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +125,000 | 125,000 |
Page 8 of 15 · 296 trades